Otaplimastat

Otaplimastat (SP-8203), a matrix metalloproteinase (MMP) inhibitor, blocks N-methyl-D-aspartate (NMDA) receptor-mediated excitotoxicity in a competitive manner. Otaplimastat also exhibits anti-oxidant activity. Otaplimastat can be used for the research of brain ischemic injury[1][2][3].

Product Specifications

CAS Number

[1176758-04-5]

Product Name Alternative

SP-8203

UNSPSC

12352005

Target

IGluR; MMP

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Cancer; Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/otaplimastat.html

Purity

98.11

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC(N(CCCN1C(NC2=C(C=CC=C2)C1=O)=O)CCCCNCCCN3C(NC4=C(C=CC=C4)C3=O)=O)=O

Molecular Formula

C28H34N6O5

Molecular Weight

534.61

References & Citations

[1]Noh SJ, et, al. SP-8203 shows neuroprotective effects and improves cognitive impairment in ischemic brain injury through NMDA receptor. Pharmacol Biochem Behav. 2011 Nov;100 (1) :73-80.|[2]Noh SJ, et, al. SP-8203 reduces oxidative stress via SOD activity and behavioral deficit in cerebral ischemia. Pharmacol Biochem Behav. 2011 Mar;98 (1) :150-4.|[3]Kim JS, et, al. Safety and Efficacy of Otaplimastat in Patients with Acute Ischemic Stroke Requiring tPA (SAFE-TPA) : A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study. Ann Neurol. 2020 Feb;87 (2) :233-245.